ドロスピレノンとは何？わかりやすく解説 Weblio辞書

ドロスピレノン

分子式：	C₂₄H₃₀O₃
その他の名称：	(6R,17S)-1,3',4',6α,7α,8β,9α,10,11,12,13,14α,15α,16α,20,21-Hexadecahydro-10β,13β-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione、ドロスピレノン、Dorospirenone、ZK-30595、Drospirenone
体系名：	17β-ヒドロキシ-3-オキソ-6β,7β:15β,16β-ビスメチレンアンドロスタ-4-エン-17-プロパン酸ラクトン、(6R,17S)-1,3',4',6α,7α,8β,9α,10,11,12,13,14α,15α,16α,20,21-ヘキサデカヒドロ-10β,13β-ジメチルスピロ[17H-ジシクロプロパ[6,7:15,16]シクロペンタ[a]フェナントレン-17,2'(5'H)-フラン]-3,5'(2H)-ジオン

「日化辞Web」で詳細を見る

ウィキペディア

索引トップランキングカテゴリー

ドロスピレノン

出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2021/08/29 07:12 UTC 版)

ドロスピレノンはプロゲスチン薬であり、経口避妊薬や更年期ホルモン療法などに使用されている^[1]^[7]。また、商品名「Slynd」として、エストロゲンとの配合剤で商品名「Yasmin」などとして^[7]^[4]、日本では商品名「ヤーズ」「ヤーズフレックス」として利用可能である（後述）。経口投与される^[1]。

脚注

^ ^a ^b ^c ^d ^e ^f ^g ^h Kuhl, H (2005). “Pharmacology of estrogens and progestogens: influence of different routes of administration”. Climacteric 8 (sup1): 3–63. doi:10.1080/13697130500148875. ISSN 1369-7137. PMID 16112947.
^ ^a ^b ^c ^d Krattenmacher, Rolf (2000). “Drospirenone: pharmacology and pharmacokinetics of a unique progestogen”. Contraception 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. ISSN 0010-7824. PMID 11024226.
^ “Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects”. Endocr. Rev. 34 (2): 171–208. (April 2013). doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s “Drospirenone tablets, for oral use”. FDA. 2019年11月12日閲覧。
^ Bachmann, Gloria (2009). “Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin”. Patient Preference and Adherence 3: 259–64. doi:10.2147/PPA.S3901. ISSN 1177-889X. PMC 2778416. PMID 19936169.
^ Wiesinger, Herbert; Berse, Matthias; Klein, Stefan; Gschwend, Simone; Höchel, Joachim; Zollmann, Frank S.; Schütt, Barbara (2015). “Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol”. British Journal of Clinical Pharmacology 80 (6): 1399–1410. doi:10.1111/bcp.12745. ISSN 0306-5251. PMC 4693482. PMID 26271371.
^ ^a ^b ^c “Drospirenone”. 2021年2月16日閲覧。
^ ^a ^b ^c ^d ^e ^f ^g “Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?”. Obstet. Gynecol. Clin. North Am. 42 (4): 683–98. (December 2015). doi:10.1016/j.ogc.2015.07.007. PMID 26598309.
^ “Drospirenone--a new progestogen with antimineralocorticoid activity. resembling natural progesterone”. Eur J Contracept Reprod Health Care 5 Suppl 3: 17-24. (December 2000). PMID 11246598.
^ “Antimineralocorticoid activity of novel oral contraceptive containing drospirenone. a unique progestogen resembling natural progesterone”. Eur J Contracept Reprod Health Care 7 Suppl 3: 19-26. discussion 42-3｜date = 2002年12月｜pmid = 12659403.
^ Enrique Ravina (11 January 2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. pp. 193–. ISBN 978-3-527-32669-3
^ Fischer, Jnos; Ganellin, C. Robin (2006) (英語). Analogue-based Drug Discovery. John Wiley & Sons. p. 459. ISBN 9783527607495
^ Robert Anthony Hatcher; Anita L. Nelson, M.D. (2007). Contraceptive Technology. Ardent Media. pp. 196–. ISBN 978-1-59708-001-9
^ ^a ^b James Q. Del Rosso; Joshua A. Zeichner (20 April 2016). Advances in Acne Management, An Issue of Dermatologic Clinics, E-Book. Elsevier Health Sciences. pp. 160–. ISBN 978-0-323-41753-2
^ “Generic Yasmin Availability”. Drugs.com. 2021年2月16日閲覧。
^ ^a ^b “Drospirenone - Exeltis USA - AdisInsight”. 2021年2月16日閲覧。
^ ^a ^b “Drospirenone/ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals - AdisInsight”. adisinsight.springer.com. 2021年2月16日閲覧。
^ Cerner Multum, Inc. (2012年6月11日). “drospirenone and ethinyl estradiol”. Auckland, New Zealand: Drugs.com. 2011年10月24日閲覧。
^ ^a ^b “Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals - AdisInsight”. adisinsight.springer.com. 2021年2月16日閲覧。
^ “ANGELIQ Tablets”. Food and Drug Administration. 2021年2月16日閲覧。
^ Maclennan, A. H.; Broadbent, J. L.; Lester, S.; Moore, V. (18 October 2004). “Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes”. The Cochrane Database of Systematic Reviews (4): CD002978. doi:10.1002/14651858.CD002978.pub2. ISSN 1469-493X. PMC 7004247. PMID 15495039.
^ Torgerson, D. J.; Bell-Syer, S. E. (13 June 2001). “Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials”. JAMA 285 (22): 2891–2897. doi:10.1001/jama.285.22.2891. ISSN 0098-7484. PMID 11401611.
^ ^a ^b “Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data”. J Br Menopause Soc 12 Suppl 1: 4–7. (March 2006). doi:10.1258/136218006775992185. PMID 16513012.
^ “Outcome and preferences in male-to-female subjects with gender dysphoria: Experience from Eastern India”. Indian J Endocrinol Metab 21 (1): 21–25. (2017). doi:10.4103/2230-8210.196000. PMC 5240066. PMID 28217493.
^ Majumder, Anirban; Chatterjee, Sudip; Maji, Debasis; Roychaudhuri, Soumyabrata; Ghosh, Sujoy; Selvan, Chitra; George, Belinda; Kalra, Pramila et al. (2020). “IDEA group consensus statement on medical management of adult gender incongruent individuals seeking gender reaffirmation as female”. Indian Journal of Endocrinology and Metabolism 24 (2): 128–135. doi:10.4103/ijem.IJEM_593_19. ISSN 2230-8210. PMC 7333765. PMID 32699777.
^ Lanza di Scalea, Teresa (June 2017). “Premenstrual Dysphoric Disorder”. Psychiatric Clinics of North America 40 (2): 201–206. doi:10.1016/j.psc.2017.01.002. PMID 28477648.
^ “Oral contraceptives containing drospirenone for premenstrual syndrome”. Cochrane Database Syst Rev (2): CD006586. (February 2012). doi:10.1002/14651858.CD006586.pub4. PMID 22336820.
^ “Effects of drospirenone/estrogen combinations on bone metabolism”. Climacteric 8 Suppl 3: 35–41. (October 2005). doi:10.1080/13697130500330283. PMID 16203654.
^ ^a ^b “Drospirenone and estradiol: a new option for the postmenopausal woman”. Climacteric 10 Suppl 1: 3–10. (February 2007). doi:10.1080/13697130601114859. PMID 17364592.
^ ^a ^b “Drospirenone in HRT?”. Drug Ther Bull 47 (4): 41–4. (April 2009). doi:10.1136/dtb.2009.03.0011. PMID 19357298.
^ “Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen”. Gynecol. Endocrinol. 23 (12): 692–9. (December 2007). doi:10.1080/09513590701582323. PMID 18075844.
^ “Drugs@FDA: FDA Approved Drug Products”. United States Food and Drug Administration. 2019年12月23日閲覧。
^ Research, Center for Drug Evaluation and. “Drug Safety and Availability - FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone” (英語). www.fda.gov. 2017年11月7日閲覧。
^ https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021098s028lbl.pdf
^ “Ethinylestradiol/drospirenone - AdisInsight”. adisinsight.springer.com. 2021年2月16日閲覧。
^ “Ethinylestradiol/drospirenone/folic acid - AdisInsight”. adisinsight.springer.com. 2021年2月16日閲覧。
^ https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022532s001lbl.pdf
^ “Yaz”. 2017年10月31日閲覧。
^ ^a ^b ^c Bayer (2013年3月25日). “Summary of Product Characteristics (SPC): Yasmin”. London: electronic Medicines Compendium (eMC), Datapharm. 2014年4月24日閲覧。 “4.3. Contraindications: • Severe chronic kidney disease or acute kidney failure. • Presence or history of severe hepatic disease as long as liver function values have not returned to normal.”
^ Bayer (2012年4月10日). “Yasmin full prescribing information”. Silver Spring, Md.: Food and Drug Administration (FDA). 2012年4月14日閲覧。 “4. Contraindications: • Renal impairment. • Adrenal insufficiency. • Liver disease.”
^ Nelson, Anita L.; Cwiak, Carrie (2011). “Combined oral contraceptives (COCs)”. In Hatcher, Robert A.; Trussell, James; Nelson, Anita L. et al.. Contraceptive Technology (20th revised ed.). New York: Ardent Media. pp. 249–341. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734
^ ^a ^b “The epidemiology of venous thromboembolism”. J. Thromb. Thrombolysis 41 (1): 3–14. (2016). doi:10.1007/s11239-015-1311-6. PMC 4715842. PMID 26780736.
^ ^a ^b ^c ^d ^e “Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis”. Aust Fam Physician 45 (1): 59–64. (2016). PMID 27051991.
^ ^a ^b “FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone” (2019年4月27日). 2021年2月16日閲覧。
^ “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”. BMJ 364: k4810. (January 2019). doi:10.1136/bmj.k4810. PMC 6326068. PMID 30626577.
^ ^a ^b “Drospirenone Litigation: Does the Punishment Fit the Crime?”. J Womens Health (Larchmt) 26 (2): 99–102. (February 2017). doi:10.1089/jwh.2016.6092. PMID 27854556.
^ ^a ^b “Hormonal contraception and thrombosis”. Fertil. Steril. 106 (6): 1289–1294. (November 2016). doi:10.1016/j.fertnstert.2016.08.039. PMID 27678035.
^ “Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose”. Thromb. Res. 165: 68–78. (May 2018). doi:10.1016/j.thromres.2018.03.005. PMID 29573722.
^ “A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception”. Int J Gynaecol Obstet 141 (3): 287–294. (June 2018). doi:10.1002/ijgo.12455. PMC 5969307. PMID 29388678.
^ ^a ^b “A review of the cardiovascular and breast actions of drospirenone in preclinical studies”. Climacteric 13 (1): 22–33. (February 2010). doi:10.3109/13697130903437375. PMID 19938948.
^ ^a ^b “Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception”. Steroids 76 (7): 636–52. (June 2011). doi:10.1016/j.steroids.2011.03.001. PMID 21414337.
^ “Progestogen safety and tolerance in hormonal replacement therapy”. Expert Opin Drug Saf 15 (11): 1515–1525. (November 2016). doi:10.1080/14740338.2016.1223041. PMID 27548404.
^ “Factors Associated with Mammographic Density in Postmenopausal Women”. J Menopausal Med 21 (2): 82–8. (August 2015). doi:10.6118/jmm.2015.21.2.82. PMC 4561745. PMID 26357645.
^ “Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells-A prospective randomized trial”. Maturitas 126: 18–24. (August 2019). doi:10.1016/j.maturitas.2019.04.205. PMID 31239112.
^ ^a ^b ^c “Progesterone and breast cancer”. Endocr. Rev. 41 (2): 320–344. (September 2019). doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725.
^ Collaborative Group on Hormonal Factors in Breast Cancer (September 2019). “Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence”. Lancet 394 (10204): 1159–1168. doi:10.1016/S0140-6736(19)31709-X. PMC 6891893. PMID 31474332.
^ “Are progestins really necessary as part of a combined HRT regimen?”. Climacteric 16 Suppl 1: 79–84. (2013). doi:10.3109/13697137.2013.803311. PMID 23651281.

[続きの解説]

「ドロスピレノン」の続きの解説一覧

ドロスピレノンのページへのリンク

ドロスピレノンとは？わかりやすく解説

ドロスピレノン

ドロスピレノン

「ドロスピレノン」の関連用語


	All Rights Reserved, Copyright © Japan Science and Technology Agency
	All text is available under the terms of the GNU Free Documentation License. この記事は、ウィキペディアのドロスピレノン (改訂履歴)の記事を複製、再配布したものにあたり、GNU Free Documentation Licenseというライセンスの下で提供されています。 Weblio辞書に掲載されているウィキペディアの記事も、全てGNU Free Documentation Licenseの元に提供されております。

ドロスピレノンとは？ わかりやすく解説

ドロスピレノン

ドロスピレノン

「ドロスピレノン」の関連用語

ドロスピレノンとは？わかりやすく解説